Dana Schmidt

oncgnostics GmbH offers cervical cancer diagnostic products and services. It engages in applying tumor-specific DNA methylation markers for cancer diagnosis and screening. The firm develops, based on proprietary epigenetic biomarkers, molecular in vitro diagnostic tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. The company was founded by Matthias Dürst, Kerstin Brox, Martina Schmitz and Alfred Hansel in February 2012 and is headquartered in Jena, Germany.

oncgnostics GmbH offers cervical cancer diagnostic products and services. It engages in applying tumor-specific DNA methylation markers for cancer diagnosis and screening. The firm develops, based on proprietary epigenetic biomarkers, molecular in vitro diagnostic tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. The company was founded by Matthias Dürst, Kerstin Brox, Martina Schmitz and Alfred Hansel in February 2012 and is headquartered in Jena, Germany.

oncgnostics GmbH offers cervical cancer diagnostic products and services. It engages in applying tumor-specific DNA methylation markers for cancer diagnosis and screening. The firm develops, based on proprietary epigenetic biomarkers, molecular in vitro diagnostic tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. The company was founded by Matthias Dürst, Kerstin Brox, Martina Schmitz and Alfred Hansel in February 2012 and is headquartered in Jena, Germany.